An observational, multi-center, open label study assessing the efficacy and safety of Lucentis (Ranibizumab intravitreal injections) in patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO)

Trial Profile

An observational, multi-center, open label study assessing the efficacy and safety of Lucentis (Ranibizumab intravitreal injections) in patients with visual impairment due to macular edema secondary to retinal vein occlusion (RVO)

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinal vein occlusion
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 22 May 2017 Status changed from recruiting to completed.
    • 12 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top